GB683523A - The manufacture of purine derivatives - Google Patents

The manufacture of purine derivatives

Info

Publication number
GB683523A
GB683523A GB2183448A GB2183448A GB683523A GB 683523 A GB683523 A GB 683523A GB 2183448 A GB2183448 A GB 2183448A GB 2183448 A GB2183448 A GB 2183448A GB 683523 A GB683523 A GB 683523A
Authority
GB
United Kingdom
Prior art keywords
carbethoxy
yields
naoh
amino
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB2183448A
Inventor
Ian Morris Heilbron
Arthur Herbert Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Research Laboratories Ltd
Original Assignee
Beecham Research Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Research Laboratories Ltd filed Critical Beecham Research Laboratories Ltd
Priority to GB2183448A priority Critical patent/GB683523A/en
Publication of GB683523A publication Critical patent/GB683523A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Purine compounds of formula (I) or (II) <FORM:0683523/IV (b)/1> <FORM:0683523/IV (b)/2> are made by reacting compounds of formula (III) or (IV) <FORM:0683523/IV (b)/3> <FORM:0683523/IV (b)/4> with an organic or inorganic basic medium preferably pyridine or an alkali hydroxide. When inorganic bases e.g. alkali hydroxides are used, subsequent acidification is necessary. Compounds (III) and (IV) are made by reacting compounds of formula (V) or (VI) <FORM:0683523/IV (b)/5> <FORM:0683523/IV (b)/6> with an isocyanate, an isothiocyanate, a urea, a thiourea or N-substituted derivative thereof, using, for example, a basic medium such as pyridine. Compounds (V) or (VI) are made by condensing compounds of formula <FORM:0683523/IV (b)/7> <FORM:0683523/IV (b)/8> with an iminoether, a thioiminoether or an amidine such as compounds of formula <FORM:0683523/IV (b)/9> <FORM:0683523/IV (b)/100> <FORM:0683523/IV (b)/111> <FORM:0683523/IV (b)/122> <FORM:0683523/IV (b)/133> In the above formul R1, R2, R3 and R4 may be the same or different and represent H, alkyl, aryl or aralkyl groups which may contain inert substituents, X may be O or S and R is H or preferably hydrocarbon such as ethyl. When R3 is H (i) and (ii) are tautomers and when R1 and R4 are H further tautomers of (i) and (ii) may be obtained. In examples: (1) ethyl aminocyanacetate is refluxed in alcoholic-chloroform solution with formamidine hydrochloride to yield 4-amino-5-carbethoxy-iminazole which is refluxed in pyridine with methyl isothiocyanate to give 4-N1-methylthioureido-5-carbethoxy-iminazole which on dissolving in 2N NaOH and acidifying with acetic acid gives 2-thio-1-methylxanthine which may also be made without isolation of the intermediates; (2) ethyl aminocyanacetate refluxed in CHCl3 with thioacetiminobenzyl ether hydrochloride yields 4-amino-5-carbethoxy-2-methyliminazole hydrochloride which is converted by the method of (i) to 4-N1-methyl-thiomido-5-carbethoxy-2-methyliminazole and to 2-thio-1 : 8-dimethylxanthine; (3) 4-amino-5-carbethoxy-2-methyliminazole is refluxed in pyridine with methyl isocyanate, dissolved in hot 10 per cent NaOH after removal of the pyridine, and acidified with acetic acid to give 1 : 8-dimethylxanthine; (4) ethyl aminocyanacetate and thiobenziminobenzyl ether hydrochloride yield 4-amino-5-carbethoxy - 2 - phenyliminazole hydrochloride which with methyl isothiocyanate gives 4-N1-methylthioureido-5-carbethoxy-2-phenyliminazole converted by dissolution in 2N NaOH and acidification to 2 - thio - 8 - phenyl - 1 - methylxanthine; (5) 4-amino-5-carbethoxy-2-phenyliminazole with methylisocyanate yields the corresponding methylureido derivative which on warming with 2N NaOH and acidification yields 1-methyl-8-phenylxanthine; (6) the iminazole of (5) with urea forms 4-ureido-5-carbethoxy-2-phenyliminazole which on treatment with 5 per cent NaOH at 80 DEG C. and subsequent acidification yields 2 : 6-dihydroxy-8-phenylpurine; (7) 4 - amino - 5 - carbethoxy-1-methyl-2-phenyliminazole is refluxed with urea in pyridine and the solid obtained on pouring into water dissolved in 2N NaOH at 80 DEG C. when on acidification 2 : 4-dihydroxy-9-methyl-8-phenylpurine is obtained; (8) the iminazole of (5) and acetylisothiocyanate yields an acetythioureido compound which is hydrolysed with 2N HCl in ethanol to the thioureidoiminazole which on warming in 2N NaOH and acidifying yields 2 - thio - 8 - phenylxanthine; (9) ethyl aminocyanacetate with phenylacetiminoethylthioether hydrochloride yields 4-amino-5-carbethoxy-2-benzyliminazole hydrochloride which with phenylisocyanate gives 4 - N1 - phenylureido - 5 - carbethoxy - 2 - benzyliminazole converted to 8-benzyl-1-phenyl-xanthine on boiling in 2N NaOH and acidifying; (10) 4-amino-5-carbethoxy-2-benzyliminazole with phenylisothiocyanate yields a phenylthioureido compound which with 2N NaOH at 90 DEG C. and acidification yields 2-thio-1-phenyl-8-benzylxanthine; (11) the same benzyliminazole is methylated either with diazomethane in methanol or dimethyl sulphate and refluxed with pyridine and methyl isothiocyanate to give a methylthioureido compound which is converted to 2-thio-1 : 7-dimethyl-8-benzylxanthine; (12) the iminazole of (5) is methylated with ethanol diazomethane to the 2-phenyl-1-methyliminazole which is converted to 4-N1-methylthioureido-5-carbethoxy-2-phenyl-1-methyl-imina zole and then to 2-thio-8-phenyl-1 : 7-dimethylxanthine as in (1); (13) ethyl aminocyanacetate with p - nitrophenylacetiminobenzylthioether hydrochloride gives 4-amino-5-carbethoxy-2-(p1-nitrobenzyl)-iminazole hydrochloride which with methylisocyanate yields 4-N1-methylureido-5-carbethoxy-2-(p1-nitrobenzyl) -iminazole converted to 8-(p1-nitrobenzyl)-1-methylxantine on boiling with 5 per cent NaOH and acidifying. Specifications 683,593 and 683,594 are referred to.
GB2183448A 1948-08-18 1948-08-18 The manufacture of purine derivatives Expired GB683523A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB2183448A GB683523A (en) 1948-08-18 1948-08-18 The manufacture of purine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2183448A GB683523A (en) 1948-08-18 1948-08-18 The manufacture of purine derivatives

Publications (1)

Publication Number Publication Date
GB683523A true GB683523A (en) 1952-12-03

Family

ID=10169590

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2183448A Expired GB683523A (en) 1948-08-18 1948-08-18 The manufacture of purine derivatives

Country Status (1)

Country Link
GB (1) GB683523A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4325956A (en) 1978-10-20 1982-04-20 Aktiebolaget Draco Method and pharmaceutical preparation for treating chronic obstructive airway disease and cardiac disease, and intermediates for the preparation of therapeutically active xanthine derivatives
US4338319A (en) 1979-11-27 1982-07-06 Aktiebolaget Draco Method for the treatment of chronic obstructive airway or cardiac diseases
US4548818A (en) * 1978-10-20 1985-10-22 Kjellin Per G Composition and methods for the treatment of chronic obstructive airway disease and cardiac disease using 3-alkylxanthines
WO2010103547A3 (en) * 2009-03-13 2010-12-02 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4325956A (en) 1978-10-20 1982-04-20 Aktiebolaget Draco Method and pharmaceutical preparation for treating chronic obstructive airway disease and cardiac disease, and intermediates for the preparation of therapeutically active xanthine derivatives
US4548818A (en) * 1978-10-20 1985-10-22 Kjellin Per G Composition and methods for the treatment of chronic obstructive airway disease and cardiac disease using 3-alkylxanthines
US4644001A (en) * 1978-10-20 1987-02-17 Aktiebolaget Draco 3-Alkylxanthines, composition and methods for the treatment of chronic obstructive-airway disease and cardiac disease
US4338319A (en) 1979-11-27 1982-07-06 Aktiebolaget Draco Method for the treatment of chronic obstructive airway or cardiac diseases
WO2010103547A3 (en) * 2009-03-13 2010-12-02 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
AU2010222289B2 (en) * 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US8859566B2 (en) 2009-03-13 2014-10-14 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US9284316B2 (en) 2009-03-13 2016-03-15 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds

Similar Documents

Publication Publication Date Title
US2485212A (en) 2-[phenthiazinyl-(n)-methyl]-imidazolines, the corresponding 2-(phenoxazinyl) imidazolines, and their salts
IE36797L (en) 1,5-benzodiazepin-2-one derivatives.
JPS5817454B2 (en) Alkylated hydroxylamine and its production method
SU557758A3 (en) Method for preparing 4-azabenzimidazoles or their salts
GB683523A (en) The manufacture of purine derivatives
US4324899A (en) 2-Amino-5-cyanothiazoles and their preparation
SU513624A3 (en) Method for preparing 2-piperazinyl thiazole derivatives
PL94634B1 (en) METHOD OF MAKING NEW ARYLPIPERAZINE DERIVATIVES OF ADENINE
US3987038A (en) Process for the preparation of {1-[5-(4-hydroxy-2H-1,2-benzothiazin-3-yl)-1,2,4-oxadiazol-3-yl]methyl}ethanone S,S-dioxide
US4477661A (en) Process for the preparation of 4-hydroxy-3-(heterocyclocarbamoyl)-2H-1,2-benzothiazine-1,1-dioxides
SU580836A3 (en) Method of preparing 4-oxybenzimidazole base-substituted derivatives or salts thereof
US3389170A (en) 3-acylamino-2, 4, 6-triiodo-benzoic acids
US3341536A (en) 2-morpholino, or piperidino alkyl sulfinyl or sulfonyl-pyridines and halo pyridines
JPS6485954A (en) Novel cinnamamide derivative and medicine containing said derivative
US4281120A (en) 7H-1,3,4-Thiadiazolo-[3,2-a]-pyrimidin-7-one-5-carboxylic compounds
US3818023A (en) 2-phenyl benzothiazolyl acetic acid derivatives
US2527265A (en) Thiazolidone compounds
US3483212A (en) 5-nitroimidazoles
US3370064A (en) Certain 4-(chlorophenylhydrazono)-2-isoxazolin-5-ones
US4845122A (en) Anti-allergy treatment using 2-(substituted amino)-4,5-dihydro-4-oxo-3-furancarboxylic acids and derivatives thereof
US2530570A (en) Pyrimidylmercapto-carboxylic acids
MISANI et al. The search for superior drugs for tropical diseases. III. Further experiments in the quinoline group
Knott 118. Polycyclic thiazoles
HU204796B (en) Process for producing benzimidazole derivatives
Reeve et al. Reaction of cyanamide with aryl (trichloromethyl) carbinols. Novel synthesis of alkyl 5-aryl-2-imino-4-oxo-1-imidazolidinecarboximidates